Indeed, in 29 multiple myeloma patients with 17p deletions, our custom capture NGS assay detected TP53 mutations in 13 patients (45%), resulting in bi-allelic TP53 inactivation. This evidence concerns the gene TP53 and plasma cell myeloma.